Focal Segmental Glomerulosclerosis Associated Seronegative Antiphospholipid Syndrome
- *Corresponding Author:
- Tausif Zar, MD
Arizona Kidney Disease and Hypertension Centers
Tucson, Arizona, USA
E-mail: [email protected], [email protected]
Received Date: August 08, 2011; Accepted Date: July 20, 2012; Published Date: July 26, 2012
Citation: Zar T, Samson W, Parke A, Sanders MM, Yamase HT (2012) Focal Segmental Glomerulosclerosis Associated Seronegative Antiphospholipid Syndrome. J Nephrol Therapeut 2:123. doi:10.4172/2161-0959.1000123
Copyright: © 2012 Zar T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Secondary Focal Segmental Glomerulosclerosis (FSGS) from thrombotic microangiopathies including Antiphospholipid Antibody Syndrome (APS), is well documented. We present a case with clinical features of APS but consistently negative serologies, suggesting ‘Seronegative APS (SNAPS)’. The patient was evaluated at the Division of Nephrology, University of Connecticut Health Center for progressive Chronic Kidney Disease (CKD). A renal biopsy exhibited thrombotic microangiopathy and associated FSGS.
Systemic thrombophilia can be primary or secondary and has an extensive list of differential diagnoses. Distinct clinical features and serologic markers characterize a particular etiology. Antiphospholipid Syndrome (APS) is the most common acquired thrombophilia. Serologic evidence of APS is the presence of commonly recognized antibodies to phospholipids in this syndrome i.e. anticardiolipin (aCL) antibodies, Lupus Anticoagulant (LA) and β2-glycoprotein 1 (β2GPI) antibodies. Rarely a patient with classic clinical features of APS does not exhibit any of the above antibodies, suggesting ‘Seronegative APS (SNAPS)’.